On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between...
"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific Welcome back to Part 2 of our special Few &...
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, talks with Will Maier, VP of Rare Disease, Drug Development...